A US KOL provides insight into the current treatment landscape for bladder cancer. Critical unmet needs in the bladder cancer market along with future trends are also discussed.
Author: Datamonitor Healthcare
Published: 31 May 2019
Number of pages:13
Report code:TL #10122
In general if people have T0, or less than T2, after having had chemotherapy their likelihood of relapse is about 10–15%, but on the other hand if they have T3, T4, or any plus disease, then their likelihood of developing metastatic disease is close to 60–70%.
I think between Keytruda and Tecentriq, the first trial to come on was Tecentriq, so even in my own practice, almost all of my patients I gave them atezolizumab, or Tecentriq, and then now we have had subsequent data that seem to sort of push Keytruda as being a more effective choice, and this has to do with level 1 evidence in the trial therapy patients… I think now it seems like maybe Keytruda is superior to Tecentriq in a lot of people’s minds, and here I think Keytruda is probably used more than Tecentriq.
I personally believe that that [failure of the IMvigor 211 trial] was a design flaw, and not that the drug is any worse, because they chose to come up with a hierarchical design, which basically goes by you have to meet your first endpoint, which was just in the PD-L1-enriched patient population. Only if you met that endpoint could you go on to your next endpoint, which is looking at the intent-to-treat full group, so this trial, Tecentriq, to a level missed the first endpoint when for the PD-L1-positive patients there was not a difference between immunotherapy versus chemotherapy… so I think Tecentriq failed by design, not by drug.
A US KOL provides insight into the current treatment landscape for bladder cancer. Critical unmet needs in the bladder cancer market along with future trends are also discussed. If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only). Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight…
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.